Are You Protecting Employees During HPAPI Manufacturing?, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, the featured speaker will discuss the planning, resources, and capabilities necessary to effectively produce a client’s highly potent active pharmaceutical ingredient (HPAPI) therapeutic, while effectively controlling the risk of exposure to operating personnel.

Xtalks Life Science Webinars

Successful manufacture of HPAPIs includes containment design and installation considerations, Best Industrial Hygiene Practices, Good Manufacturing Practices, and the process of characterizing, challenging, and verifying isolator performance.

In this webinar, Tom Evans, MS, CMMS, an expert in hazardous manufacturing controls, will discuss the planning, resources, and capabilities necessary to effectively produce a client’s highly potent active pharmaceutical ingredient (HPAPI) therapeutic, while effectively controlling the risk of exposure to operating personnel. Controlling exposure is a critical factor in successfully bringing many of today’s novel, highly potent drugs to the clinic and eventually to the commercial market. Successful manufacture of HPAPIs includes containment design and installation considerations, Best Industrial Hygiene Practices, Good Manufacturing Practices, and the process of characterizing, challenging, and verifying isolator performance.

The biopharma industry has increasingly moved toward more potent and selective active pharmaceutical ingredients, and while this has had great therapeutic advantage, it can pose risks to those employees who manufacture these HPAPIs and final drug products. It can also be challenging for drug developers to locate contract manufacturing services that are able to manage the very low occupational exposure levels (OEL) associated with these unique products. This is a particularly challenging dilemma when developing and manufacturing highly potent injectable and infused biologics. The crossroads of current Good Manufacturing Practices (cGMP) and low OELs can be some of the most complex engineering, product quality, and industrial hygiene challenges found within in the pharma industry. Developing containment strategies that allow employees to work with these therapeutics in a production environment and effectively control the risk of exposing them to occupational illness must be a sustained business focus.

Join Tom Evans, MS CHMM, Director Safety, Health & Environment, Ajinomoto Bio-Pharma Services in a live webinar on Tuesday, August 25, 2020 at 11am EDT (4pm BST/UK).

For more information or to register for this event, visit Are You Protecting Employees During HPAPI Manufacturing?

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
Xtalks
+1 (416) 977-6555 x 352
Email >
Visit website